Sector
PharmaceuticalsOpen
₹1,611.05Prev. Close
₹1,611.05Turnover(Lac.)
₹2,461.59Day's High
₹1,625Day's Low
₹1,61052 Week's High
₹1,681.652 Week's Low
₹1,132Book Value
₹359.48Face Value
₹2Mkt Cap (₹ Cr.)
1,31,171.96P/E
32.78EPS
49.18Divi. Yield
0.81On February 6, 2023, Cipla informed exchanges that I-T department officials had searched some of company offices and manufacturing units.
Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 161.47 | 161.43 | 161.36 | 161.29 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 27,812.45 | 24,476.66 | 22,352.19 | 19,766.27 |
Net Worth | 27,973.92 | 24,638.09 | 22,513.55 | 19,927.56 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Revenue | 13,091.79 | 11,302.71 | 12,659.15 | 11,389.9 |
yoy growth (%) | 15.82 | -10.71 | 11.14 | 5.77 |
Raw materials | -5,090.24 | -4,103.61 | -4,319.21 | -4,155.49 |
As % of sales | 38.88 | 36.3 | 34.11 | 36.48 |
Employee costs | -1,729.16 | -1,703.58 | -1,911.08 | -1,785.94 |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Profit before tax | 3,546.23 | 2,784 | 2,964.31 | 1,988.92 |
Depreciation | -460.01 | -468.62 | -599.78 | -529.61 |
Tax paid | -856.84 | -739.35 | -646.14 | -442.88 |
Working capital | 1,126.76 | -61.34 | 1,238.17 | 865.57 |
Other operating items |
Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 15.82 | -10.71 | 11.14 | 5.77 |
Op profit growth | 9.74 | 13.3 | 23.3 | 37.54 |
EBIT growth | 26.3 | -5.7 | 49.95 | 63.18 |
Net profit growth | 19.83 | 6.47 | 57.85 | 50.62 |
Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
---|---|---|---|---|---|
Gross Sales | 25,446.63 | 22,473.18 | 21,623.36 | 18,988.52 | 16,694.85 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 25,446.63 | 22,473.18 | 21,623.36 | 18,988.52 | 16,694.85 |
Other Operating Income | 327.46 | 279.94 | 139.98 | 171.07 | 437.14 |
Other Income | 746.57 | 475.45 | 280.91 | 265.99 | 344.2 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,824.55 | 157.19 | 4,37,482.74 | 237.82 | 0.74 | 4,409.74 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 5,137.8 | 82.16 | 1,36,472.09 | 430 | 0.58 | 2,063 | 507.93 |
Cipla Ltd CIPLA | 1,611.05 | 32.78 | 1,30,170.58 | 1,055.94 | 0.81 | 3,752.25 | 346.4 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,416.7 | 76.94 | 1,15,641.61 | 469 | 0.82 | 2,394 | 201.77 |
Dr Reddys Laboratories Ltd DRREDDY | 6,667.15 | 27.02 | 1,11,298.04 | 1,417.2 | 0.6 | 5,823.9 | 1,458.61 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman (Non-Executive)
Y K Hamied
Vice Chairman
M K Hamied
Non-Exec. & Independent Dir.
Adil Zainulbhai
Non-Exec. & Independent Dir.
Punita Lal
Managing Director & Global CEO
Umang Vohra
Company Sec. & Compli. Officer
Rajendra Chopra
Independent Director
Robert A Stewart
Independent Director
P R Ramesh
Independent Director
Mandar Purushottam Vaidya
Non Executive Director
Samina Hamied
Additional Director
Abhijit A Joshi
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Cipla Ltd
Summary
Cipla Ltd is one of the leading pharmaceutical companies in India. The Company is in the business of manufacturing, developing, and marketing wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs). Ciplas product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments. With a rich portfolio, it is deepening presence in the home markets of India, as well as South Africa, North America, and other key regulated and emerging markets. Its 47 manufacturing sites around the world produce more than 50 dosage forms and over 1,500 products across wide range of therapeutic categories. Cipla Ltd was incorporated in the year 1935 with the name Chemical, Industrial & Pharmaceutical Laboratories Ltd. Khwaja Abdul Hamied, the founder of Cipla gave the company all his patent and proprietary formulas for several drugs and medicines, without charging any royalty. On August 17, 1935, Cipla was registered as a public limited company with an authorized capital of Rs 6 lakh. From its first manufacturing unit at Bombay Central in 1936, Cipla now has over 40 state-of-the art manufacturing facilities across the globe including India, USA, China and South Africa.In the year 1941, as the Second World War cuts off drug supplies, the company starts producing fine chemicals, dedicating all its facilities for the war effort. In the year 1952, the company se
Read More
The Cipla Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹1624.3 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Cipla Ltd is ₹131171.96 Cr. as of 09 Sep ‘24
The PE and PB ratios of Cipla Ltd is 32.78 and 4.65 as of 09 Sep ‘24
The 52-week high/low is the highest and lowest price at which a Cipla Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Cipla Ltd is ₹1132 and ₹1681.6 as of 09 Sep ‘24
Cipla Ltd's CAGR for 5 Years at 27.67%, 3 Years at 19.24%, 1 Year at 28.19%, 6 Month at 8.47%, 3 Month at 9.08% and 1 Month at 5.17%.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
Invest wise with Expert advice